Shankar Varadharajan and his Persons Acting in Concert (PACs) have further increased their aggregate shareholding in Fischer Medical Ventures Limited to 63.08% of the total voting capital, following an additional acquisition of shares via warrant conversion. This latest transaction, completed on August 17, 2026, involved the preferential allotment of 4,54,210 equity shares to FMV Holdings Pte Ltd. Mr. Varadharajan’s individual holding remains unchanged at 12.31%, while FMV Holdings Pte Ltd increased its stake from 50.74% to 50.78%. This move completes the conversion of all warrants held by the promoter group, consolidating their control over the Chennai-based medical device manufacturer.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with both the BSE Limited and the National Stock Exchange of India Limited. The acquisition was executed through the conversion of the remaining warrants held by FMV Holdings Pte Ltd into equity shares. Consequently, FMV Holdings’ warrant holdings decreased from 4,54,210 to 0. Mr. Varadharajan and Mr. Ravindran Govindan saw no change in their equity or warrant positions during this specific transaction.

Shareholding Structure Post-Acquisition

The table below details the updated shareholding pattern of the acquirer and PACs:

Post-acquisition, the promoter group holds no warrants or other convertible instruments. There are no encumbrances, pledges, or liens on any of the shares held by the acquirer or PACs.

Capital Structure Changes

The acquisition resulted in a final increase in the company’s issued equity capital. Prior to this allotment, Fischer Medical Ventures Limited’s equity share capital stood at ₹69,82,31,260, divided into 69,82,31,260 equity shares of Re. 1 each. Following the conversion of the remaining warrants, the total equity share capital increased to ₹69,86,85,470, comprising 69,86,85,470 equity shares. The total diluted share/voting capital now matches the basic equity capital at ₹69,86,85,470, as there are no outstanding convertible securities.

What the Numbers Show

The complete conversion of all outstanding warrants by the promoter group eliminates future dilution risk for minority shareholders associated with these instruments. With the promoter group now holding a two-thirds majority in voting rights (63.08%) and zero convertible securities, the capital structure is stabilized. The alignment of basic and diluted voting capital indicates that no further equity dilution will occur from existing warrant conversions, providing clarity on the promoter group's consolidated control over corporate governance decisions.

Fischer Medical Ventures reported a substantial expansion in its first-quarter revenue, logging ₹819 million against ₹234 million in the same period of the previous fiscal year. This represents a year-on-year growth of approximately 250% in topline figures. However, the bottom line contracted during the period, with consolidated net profit falling to ₹38 million from ₹50 million recorded in the prior year’s quarter.

The divergence between revenue and profitability suggests a compression in margins or increased operational costs during the quarter, although specific expense line items were not disclosed in the brief filing. The company did not report any dividend payout or provide guidance on future performance in this update.

What the Numbers Show

The data reveals a clear disconnect between sales volume and retained earnings. While revenue more than tripled, net profit declined by 24%. This indicates that the incremental revenue generated in Q1 did not translate into proportional profit growth, pointing to potential margin pressure or higher input costs associated with the expanded business activity.